The Disappointing Reality of Crowdfunding Cancer Care
If crowdfunding doesn’t work, here’s how oncologists can help patients with financial toxicity.
Endocrine Cancer
ENDOCRINE CANCER ADVISOR
FEATURED CONTENT
-
-
Some Targeted Therapies May Miss the Mark
Ten different drugs continued to kill cancer cells even when their target proteins were removed. -
Pathologists Need Better Reporting Guidelines for Postneoadjuvant Chemotherapy Specimens
Measuring a tumor’s response to neoadjuvant chemotherapy can be prognostic, providing important clues about a patient’s likely outcome following treatment. -
Cognitive Impairment Following Immunotherapy Treatment May Be Underestimated
As more and more patients undergo immunotherapy treatments, understanding possible side effects on cognitive function is an important research gap. -
Knowing the Appropriateness of Running Noninferiority Trials in Oncology
Researches took a critical look at noninferiority trials and determined that when a new intervention is “not worse,” the possibility exists that it is not better, either.
ENDOCRINE CANCER NEWS
Many Perceive Lack of Choice in Receipt of RAI for Thyroid Cancer
Once-Weekly Exenatide Treatment Does Not Increase Risk for Medullary Thyroid Carcinoma
Cumulative Risk for Thyroid Cancer After Initial Benign Thyroid Biopsy
Lenvatinib Active in Rare Adenoid Cystic Carcinoma
High Response Rate for Patients With High-Grade Neuroendocrine Cancer Receiving Dual Immune Checkpoint Blockade
Want to read more?
Please login or register first to view this content.
